Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01413815
Other study ID # UKE-KP 2009/001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2010
Est. completion date September 2012

Study information

Verified date June 2022
Source Universitätsklinikum Hamburg-Eppendorf
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to test whether pre-operative oral supplementation with L-arginine results in a significant reduction of peri-operative cardiovascular complication rate in unselected patients undergoing major abdominal or thoracic (non-cardiac) surgery. The second aim of the study is to assess whether pre-operative determination of plasma ADMA levels allows to identify patients who are at high risk of experiencing a peri-operative complication, and whether this subgroup of patients profits specifically from pre-operative L-arginine supplementation.


Description:

Patients will be recruited for this study from the participating Departments. In a previous study (protocol no. UKE-KP 2002/006) we investigated the predictive role of ADMA (asymmetric dimethylarginine) for peri-operative complications in unselected patients undergoing major surgery. The major result of that study was that patients with pre-operative ADMA plasma level within the highest quartile of the distribution had a significantly elevated risk of experiencing a serious peri-operative complication within a period of 30 days after the surgical intervention. These data have been published [Maas et al. 2007]. As ADMA competitively displaces L-arginine from the enzyme, NO synthase, it is expected that the adverse cardiovascular effects of high ADMA levels can be antagonized by supplemental L-arginine. Therefore, the present study was designed to specifically address the question whether dietary supplementation with L-arginine before the surgery, aiming at replenishing the body's L-arginine stores, may help to reduce the peri- operative complication rate. Another aim is to assess whether this occurs in all patients or specifically in the subgroup with elevated baseline ADMA levels. Study participants will be recruited from patients who routinely visit the outpatient clinic at the participating Departments of Anesthesiology and Intensive Care in advance of their planned surgical intervention. Patients usually visit the clinic between five working days in advance of the scheduled time of surgery, or they are admitted to in-patient treatment one or two days before the surgery. They will be informed about the scope and aim of the study, and after having given their informed consent, patients will receive L-arginine dietary supplements or corresponding placebo according to randomisation plan for the time until surgery. The last dosage of the L-arginine supplements will be taken in the morning of the surgery, dissolved in a glass of tap water that patients ware required to drink with premedication for anesthesia. Blood samples to measure plasma L-arginine and ADMA levels will be taken at the time of inclusion, in the morning before scheduled surgery, and on days 1 and 3 after the surgery and will together with additional safety parameter not exceed 80ml. No administration of study product will occur after surgery. After surgery having taken place, patients will be monitored daily for as long as they remain being treated as in-patients, and all clinical events, changes in laboratory parameters, and apparatively performed clinical tests as scheduled according to clinical routine will be documented. No additional clinical treating will be performed on study participants, except the blood samples that will be taken as described above. After discharge, patients will be followed-up telephonically, for the last time at 30 days after the date of surgery. All clinical events occurring in this period will be recorded. In addition, changes in laboratory values, ECG recordings, and other apparative diagnostic measures will be checked for possible complications, and also be recorded.


Recruitment information / eligibility

Status Completed
Enrollment 269
Est. completion date September 2012
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender All
Age group 30 Years to 75 Years
Eligibility Inclusion Criteria: - male and female subjects aged between 30 and 75 years; - scheduled major thoracic (non-cardiac), abdominal, or two cavity surgery; - ASA risk class II- IV; - efficient birth control for women in child-bearing age; - signed written informed consent form. Exclusion Criteria: - participation in a clinical study within the last 3 months before inclusion into the present study; - high allergic tendency in the medical history at the investigators discretion; - patients with known diabetic retinopathy; - previous abuse of drugs or alcohol; - pregnancy or nursing; - any severe consuming disease (malignant or non-malignant) that reduces the patient's life expectancy to a level which makes it uncertain that the patient would survive the 30 day period even without surgery; - any somatic or psychic disease that may hamper participation in the study or compliance; - active liver disease or hepatic failure (serum AST or ALT >1.5-fold above the upper limit of the normal range); - severe renal failure (calculated creatinine clearance < 30 ml/min [Cockcroft-Gault formula]), nephrotic syndrome or dysproteinemia; - previous intolerance of L-arginine or L-citrulline.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
L-arginine
3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
Other:
Placebo
3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)

Locations

Country Name City State
Germany Institut für Experimentelle und Klinische Pharmakologie,Universitätsklinikum Hamburg-Eppendorf Hamburg
Germany Klinik für Anästhesie und operative Intensivmedizin,Asklepios Klinik Nord, Standort Heidberg Hamburg
Germany Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie,Kath. Marienkrankenhaus gGmbH Hamburg
Germany Klinik und Poliklinik für Anästhesiologie, Universitätsklinikum Hamburg-Eppendorf Hamburg
Germany Klinik für Anästhesiologie,Städtisches Klinikum Lüneburg Lüneburg Niedersachsen

Sponsors (1)

Lead Sponsor Collaborator
Universitätsklinikum Hamburg-Eppendorf

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Appel D, Böger R, Windolph J, Heinze G, Goetz AE, Hannemann J. Asymmetric dimethylarginine predicts perioperative cardiovascular complications in patients undergoing medium-to-high risk non-cardiac surgery. J Int Med Res. 2020 Aug;48(8):300060520940450. d — View Citation

Maas R, Dentz L, Schwedhelm E, Thoms W, Kuss O, Hiltmeyer N, Haddad M, Klöss T, Standl T, Böger RH. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery. Crit Care Med. 2007 Aug;35(8):1876-81. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary difference in incidence of the combined end-point of death of any cause the difference in incidence of the combined end-point of death of any cause, acute myocardial infarction or acute coronary syndrome, decompensated heart failure, cardiac arrest or resuscitation, and cerebral or pulmonary embolism between L-arginine and placebo. period of 30 days after surgery
Secondary difference in incidence between L-arginine and placebo (subgroup with ADMA) difference in incidence between L-arginine and placebo for the subgroups with ADMA below and above the median concentration period of 30 days after surgery
Secondary difference in incidence between beta-blocker or no beta-blocker treatment the difference in incidence of the combined primary end-point between patients on beta-blocker treatment or not on beta-blocker treatment period of 30 days after surgery
Secondary difference in incidence between statin treatment or no statine treatment the difference in incidence of the combined primary end-point between patients on statin treatment or not on statin treatment period of 30 days after surgery
Secondary difference in incidence between L-arginine and placebo (ASA class) -the difference in incidence of the combined primary end-point between L-arginine and placebo for each of the ASA classes II to IV period of 30 days after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05243446 - Cardiorenal Effecs of Losartan in Kidney Transplant Recipients
Completed NCT06089226 - Parameters Related to Physical Activity Level in SCI
Recruiting NCT04696081 - Atrial Fibrillation in Active Cancer Patients
Completed NCT05687097 - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
Completed NCT03274869 - Scrub Typhus Infection Induced Cardiovascular Disease
Completed NCT04025086 - Perioperative Goal Directed Therapy (PGDT) in Spinal Surgery in the Prone Position
Completed NCT03010969 - Perioperative Endothelial Dysfunction in Patients Undergoing Major Acute Abdominal Surgery
Recruiting NCT05077748 - An 18-year Follow-up Study on OSA in a Population-based Cohort
Not yet recruiting NCT06279000 - Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery Phase 3
Enrolling by invitation NCT06360666 - Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia
Recruiting NCT03977337 - Perioperative Pulmonary Monitoring in Major Emergency Surgery
Recruiting NCT05996965 - Evaluation of Clinical Utility of Non-invasive Hemodynamic Monitoring Device
Recruiting NCT05349955 - Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community N/A
Withdrawn NCT04435015 - The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Phase 1/Phase 2
Active, not recruiting NCT05745090 - N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) in Type 2 Diabetes Mellitus
Terminated NCT03760159 - Minimally Invasive Detection of a Sleep Apnoea
Completed NCT04802122 - Induction of Anesthesia With Sevoflurane Preserving Spontaneous Breathing: Cardiorespiratory Effects. Phase 4
Not yet recruiting NCT06419270 - Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism
Recruiting NCT05895669 - Cardiovascular Outcomes in Orthotopic Liver Transplanted Patients (COLT Study)
Completed NCT05685979 - Evaluation of Cardiac Functions in Deep Trendelenburg Position